Literature DB >> 20487601

New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades.

Mel Spigelman, Raymond Woosley, Jan Gheuens.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20487601

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


× No keyword cloud information.
  14 in total

1.  Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.

Authors:  Mary A De Groote; Veronica Gruppo; Lisa K Woolhiser; Ian M Orme; Janet C Gilliland; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

Review 2.  The challenge of new drug discovery for tuberculosis.

Authors:  Anil Koul; Eric Arnoult; Nacer Lounis; Jerome Guillemont; Koen Andries
Journal:  Nature       Date:  2011-01-27       Impact factor: 49.962

3.  Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.

Authors:  Rokeya Tasneen; Si-Yang Li; Charles A Peloquin; Dinesh Taylor; Kathy N Williams; Koen Andries; Khisimuzi E Mdluli; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

Review 4.  Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis.

Authors:  Mageshwaran Lakshmanan; Alphienes Stanley Xavier
Journal:  J Young Pharm       Date:  2013-12-30

5.  A physiologically based pharmacokinetic model of rifampin in mice.

Authors:  Michael A Lyons; Brad Reisfeld; Raymond S H Yang; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

6.  Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.

Authors:  Kathy Williams; Austin Minkowski; Opokua Amoabeng; Charles A Peloquin; Dinesh Taylor; Koen Andries; Robert S Wallis; Khisimuzi E Mdluli; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

Review 7.  Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis.

Authors:  Nicholas D Walter; Michael Strong; Robert Belknap; Diane J Ordway; Charles L Daley; Edward D Chan
Journal:  Respirology       Date:  2012-07       Impact factor: 6.424

8.  Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model.

Authors:  Michael A Lyons; Anne J Lenaerts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-05-31       Impact factor: 2.745

9.  Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis.

Authors:  Koen Andries; Tom Gevers; Nacer Lounis
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

10.  Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis.

Authors:  Payam Nahid; Erin Bliven-Sizemore; Leah G Jarlsberg; Mary A De Groote; John L Johnson; Grace Muzanyi; Melissa Engle; Marc Weiner; Nebojsa Janjic; David G Sterling; Urs A Ochsner
Journal:  Tuberculosis (Edinb)       Date:  2014-02-07       Impact factor: 3.131
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.